Article
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.
American journal of hematology - 1 Sept 2026
Hoff Fieke W, Zeidner Joshua F, Torlapati Geeta, Nicolet Deedra, Mrózek Krzysztof, Huang Ying, Li Alexander, Welkie Rina Li, Swords Ronan T, Traer Elie, Stein Eytan M, Lin Tara L, Baer Maria R, Duong Vu H, Blum William G, Arellano Martha L, Stock Wendy, Odenike Olatoyosi, Olin Rebecca L, Smith Catherine C, Schiller Gary J, Curran Emily K, Chan Onyee, McMahon Christine, Hochman Michael, Sahasrabudhe Kieran, Foucar Charles, Gonzalez-Lugo Jesus, Knick Ragon Brittany, Handa Shivani V, Heerema Nyla A, Chen Timothy, Martycz Molly, Stefanos Mona, Marcus Sonja G, Rosenberg Leonard, Druker Brian J, Levine Ross L, Burd Amy, Yocum Ashley O, Borate Uma M, Mims Alice S, Eisfeld Ann-Katrin, Byrd John C, Madanat Yazan F
Abstract excerpt
Frameshift mutations in exon 12 of nucleophosmin 1 (NPM1 mut) are among the most common mutations in acute myeloid leukemia (AML) and have historically been considered favorable-risk in the absence of FLT3-ITD. In the European LeukemiaNet (ELN) 2024 risk-classification for patients treated with hypomethylating agents plus venetoclax (HMA + VEN), NPM1 mut is not considered favorable when co-occurring with...
Topics
Join the communities discussing this publication.